The DOI matches its Crossref record.
Mutations in Diphtheria Toxin Separate Binding from Entry and Amplify Immunotoxin Selectivity
Abstract
Monoclonal antibodies linked to toxic proteins (immunotoxins) can selectively kill some tumor cells in vitro and in vivo. However, reagents that combine the full potency of the native toxins with the high degree of cell type selectivity of monoclonal antibodies have not previously been designed. Two heretofore inseparable activities on one polypeptide chain of diphtheria toxin and ricin account for the failure to construct optimal reagents. The B chains (i) facilitate entry of the A chain to the cytosol, which allows immunotoxins to efficiently kill target cells, and (ii) bind to receptors present on most cells, which imparts to immunotoxins a large degree of non-target cell toxicity. This report identifies point mutations in the B polypeptide chain of diphtheria toxin that block binding but allow cytosol entry. Three mutants of diphtheria toxin have 1/1,000 to 1/10,000 the toxicity and 1/100 to 1/8,000 the binding activity of diphtheria toxin. Linking of either of two of the inactivated mutant toxins (CRM103, Phe 508 ; CRM107, Phe 390 , Phe 525 ) to a monoclonal antibody specific for human T cells reconstitutes full target-cell toxicity—indistinguishable from that of the native toxin linked to the same antibody—without restoring non-target cell toxicity. This separation of the entry function from the binding function generates a uniquely potent and cell type-specific immunotoxin that retains full diphtheria toxin toxicity, yet is four to five orders of magnitude less toxic than the native toxin is to nontarget cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The crystal structure of diphtheria toxin
Choe, S., Bennett, M. J., Fujii, G., Curmi, P. M. G., Kantardjieff, K. A., Collier, R. J., & Eisenberg, D. (1992) · Nature · doi:10.1038/357216a0 · Cited by 669
Laske, D. W., Youle, R. J., & Oldfield, E. H. (1997) · Nature Medicine · doi:10.1038/nm1297-1362 · Cited by 525
Self-citationThe transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells
Daniels, T. R., Delgado, T., Helguera, G., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.006 · Cited by 518
Chloroquine and its analogs: A new promise of an old drug for effective and safe cancer therapies
Solomon, V. R., & Lee, H. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.063 · Cited by 516
Bacteria in cancer therapy: a novel experimental strategy
Patyar, S., Joshi, R., Byrav, D. P., Prakash, A., Medhi, B., & Das, B. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-21 · Cited by 340
Mehta, A. M., Sonabend, A. M., & Bruce, J. N. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0520-4 · Cited by 331
Frerichs, K. U., Smith, C. B., Brenner, M., DeGracia, D. J., Krause, G. S., Marrone, L., Dever, T. E., & Hallenbeck, J. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14511 · Cited by 325
Immunotoxins for targeted cancer therapy
Kreitman, R. J. (2006) · The AAPS Journal · doi:10.1208/aapsj080363 · Cited by 307
Transferrin Receptor Ligand-Targeted Toxin Conjugate (Tf-CRM107) for Therapy of Malignant Gliomas
Weaver, M., & Laske, D. W. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1026246500788 · Cited by 299
Recombinant Toxins for Cancer Treatment
Pastan, I., & FitzGerald, D. (1991) · Science · doi:10.1126/science.1683495 · Cited by 299
Wagner, E., Curiel, D., & Cotten, M. (1994) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(94)90008-6 · Cited by 275
Iwamoto, R., Higashiyama, S., Mitamura, T., Taniguchi, N., Klagsbrun, M., & Mekada, E. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06516.x · Cited by 265
Effect of therapeutic macromolecules in spheroids.
Fracasso, G. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00084-6 · Cited by 46
Metadata
- Authors
- Greenfield, L., Johnson, V. G., & Youle, R. J.
- Venue
- Science
- Published
- 1987-10-23
- Volume
- 238
- Issue
- 4826
- Pages
- 536-539
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2079971708
- Cited by
- 173
- References
- 0
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.